Semaglutide

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a synthetic analogue of the human GLP-1 hormone, modified to extend its half-life to approximately one week (for injectable formulations), allowing for convenient once-weekly dosing.

Unlike many peptides discussed on this site, semaglutide is an FDA-approved prescription medication with an extensive body of clinical evidence from thousands of patients across dozens of clinical trials.

How Semaglutide Works

Semaglutide mimics the action of the naturally occurring GLP-1 hormone:

• Insulin stimulation: Enhances glucose-dependent insulin secretion from pancreatic beta cells
• Glucagon suppression: Reduces glucagon release, lowering hepatic glucose production
• Gastric emptying: Slows the rate at which food leaves the stomach, reducing post-meal glucose spikes
• Appetite regulation: Acts on GLP-1 receptors in the brain (particularly the hypothalamus and brainstem) to reduce hunger and food intake
• Weight loss: Multiple mechanisms converge to produce significant, sustained weight reduction

Clinical Evidence

Weight Loss

The landmark STEP trials demonstrated that semaglutide 2.4mg (Wegovy) produced an average weight loss of approximately 15% of body weight over 68 weeks — a level of efficacy previously seen only with bariatric surgery.

Diabetes Management

Semaglutide provides potent HbA1c reduction (typically 1.5–2.0% decrease) and is considered a first-line agent in many type 2 diabetes treatment guidelines.

Cardiovascular Benefits

The SUSTAIN-6 and SELECT trials demonstrated significant reductions in major adverse cardiovascular events (MACE) in high-risk patients.

Common Side Effects

• Nausea (most common, typically subsides over weeks)
• Vomiting and diarrhea
• Constipation
• Injection site reactions
• Fatigue

Serious Risks to Know

• Pancreatitis: Rare but reported; discontinue if suspected
• Thyroid tumors: C-cell tumors seen in rodent studies; contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2
• Gallbladder disease: Increased risk of cholelithiasis
• Severe GI effects: Can occur in rare cases

Medical Disclaimer: Semaglutide is a prescription medication. This content is for educational purposes only. Only use semaglutide under the supervision of a licensed healthcare provider.

Compounding & Shortage Issues

The popularity of semaglutide led to significant drug shortages from 2022–2024, during which many compounding pharmacies produced semaglutide. The FDA has raised concerns about the safety of compounded semaglutide, and Novo Nordisk has taken legal action against multiple compounders. Always obtain semaglutide from licensed pharmacies with valid prescriptions.

Related Reading

• GLP-1 Agonists Explained: Semaglutide and Tirzepatide — Side-by-side comparison of semaglutide and tirzepatide mechanisms and outcomes
• GLP-1 Patient Guide: What to Expect — Practical guide to starting semaglutide: titration, side effects, and long-term use
• Stopping GLP-1 Therapy: Weight Regain and Maintenance Strategies — SURMOUNT-4 and STEP 4 discontinuation data: what happens when you stop
• GLP-1 2026 Clinical Data: Tirzepatide vs. Semaglutide — SURMOUNT-5 head-to-head results and SELECT cardiovascular extension data
• GLP-1 and Muscle Loss: Preserving Lean Mass — Managing body composition during semaglutide therapy
• GLP-1 Agonists and Brain Health: Parkinson’s, Alzheimer’s, and Addiction Research — Emerging neurological applications and clinical trial data
• GLP-1 Pharmacogenomics: Why Response Varies — Genetic and metabolic factors that influence semaglutide response